תוצאות חיפוש עבור זידובודין

אנחנו לא מתרגשים מאזנימים תקינים לא מחשפים בעיות כשאין - אם יופיעו יהיה צורך בתגובה בהתאם

שלום להלן תגבותו של פרופ' איזביצקי : "הטיפול הטוב ביותר הוא פרדניזון. במידה ולא ניתן לתת סטרואידים ישנם טיפולים אחרים לסרקוידוזיס כגון: Methotrexate Chloroquine AZT Cyclosporine ועוד כל טוב ורפואה שלמה פרופ' איזביצקי"

שלום רוקי, 1. הופעת אדמומיות בלחיים כשבוע לאחר תחילת טיפול ב'קומביויר + קלטרה' יכולה להיות קשורה לטיפול זה. 2. בנוגע לשאלתך על המשך הטיפול, אני מציע לך להפנותה לרופא/ה שרשם/ה לך אותו. הרבה בריאות אפי

המבנה המולקולרי של תרופות הוא מעבר לידע שלי. בעיקרון זו תרופה שמונעת את הרפליקציה של שרשרת ה RNA של הנגיף. משמש בעיקר לטיפול ב HIV כחלק מה"קוקטייל" שנותנים.

שלום שי תוכל לפנות אל יבואנית התרופה - פרומדיקו בע"מ. הכתובת: בלטימור 4 פתח תקוה לימור איזנבוד

אין התקדמות במה שנוגע לריפוי. יש נסיונות בשיטות טיפול שונות, ביניהן שילוב של AZT ואינטרפרון שנראה כי מאריך את החיים (הטיפול מכוון נגד הוירוס), אבל לא כל המחקרים הראו אותו שיעור של "הצלחה". לגבי השתלת מח עצם - אין הרבה נסיון בזה ובודאי שאי אפשר לענות לשאלה בהתייחסות ישירה לאמך ז"ל (האם השתלה היתה מועילה לה ?). הנה תקציר של מאמר בנושא לגבי 10 חולים ולאחרין תאור מקרה של חולה בודד שהושתל בהצלחה. שאלה חשובה בנושא זה היא השפעת הוירוס על התאים החדשים לאחר ההשתלה. Bone Marrow Transplant 2001 Jan;27(1):15-20 Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, Tara M, Kawano F, Saburi Y, Kikuchi H, Hara M, Sao H, Morishima Y, Kodera Y, Sonoda S, Tomonaga M Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Adult T cell leukemia/lymphoma (ATL) is a poor prognosis T cell malignancy. In order to improve the outcome, we employed allogeneic stem cell transplantation (allo-SCT) for ATL in 10 patients, nine of whom were from HLA-identical siblings and one from an unrelated donor. Conditioning regimens varied among the patients except that all received total body irradiation. The patients tolerated the regimens well with mild, if any toxicity, and engraftment occurred in all cases. Median leukemia-free survival after allo-SCT was 17.5+ months (range 3.7-34.4+). Six of the 10 patients developed acute GVHD (one case each with grade I, III or IV, and three cases with grade II) and three patients developed extensive chronic GVHD. Four patients died after allo-SCT during the study period from either acute GVHD (grade IV), pneumonitis, gastrointestinal bleeding or renal insufficiency. Two of the 10 cases with no symptoms of GVHD relapsed with clinical ATL. These results strongly suggest that allo-SCT may improve the survival in ATL if a controlled degree of GVHD develops. ************************************** Int J Hematol 2000 Apr;71(3):290-3 Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation. Tajima K, Amakawa R, Uehira K, Matsumoto N, Shimizu T, Miyazaki Y, Fujimoto M, Kishimoto Y, Fukuhara S First Department of Internal Medicine, Kansai Medical University, Osaka, Japan. Adult T-cell leukemia (ATL) is associated with human T-cell leukemia virus type 1 (HTLV-1) and is known to be a refractory disease of highly poor prognosis. We describe a case of ATL treated with allogeneic bone marrow transplantation (allo-BMT). The allo-BMT successfully induced complete remission in the patient. Currently, at 24 months post BMT, there has been no evidence of minimal residual disease (MRD) detected by polymerase chain reaction (PCR) assay for the T-cell receptor gamma chain gene. By contrast, PCR analysis demonstrated the reappearance of the cells harboring the integrations of the HTLV-1 proviral DNA 9 months after the BMT. These findings may imply a reversion to the carrier state rather than the recurrence of the leukemia from the MRD. The clinical consequence of our case illustrates that allo-BMT is an effective therapy, at least for achieving longer disease-free survival in ATL. ************************************** אינני יודע כמה חולים יש בארץ. ************************************* ראה תקצירים עדכניים בנושא: Virus Res 2001 Nov;78(1-2):79-92 Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives. Bazarbachi A, Hermine O Department of Internal Medicine, American University of Beirut, PO Box 113, 6044, Beirut, Lebanon [Medline record in process] Human T-cell leukaemia virus type I (HTLV-I) associated adult T-cell leukaemia/lymphoma (ATL) carries a very poor prognosis due to an intrinsic resistance of leukaemic cells to conventional or even high doses of chemotherapy and to an associated severe immunosuppression. Therefore, the potential role of conventional chemotherapy, high dose chemotherapy with autologous or allogeneic bone marrow transplantation remains to be defined. Important progress was achieved in the treatment of ATL with the combination of zidovudine (AZT) and interferon-alpha (IFN) which produces a high response rate in ATL patients with minimal side effects. This treatment seems to prolong the survival of patients much more than intensive chemotherapy. The success of this potentially anti-retroviral approach in the treatment of ATL suggests the existence of continuous HTLV-I replication in vivo. These encouraging results may be improved by the use of higher doses of AZT and IFN combined with other anti-retroviral agents. However, since cure seems still elusive, new therapeutic approaches or new combinations are required. For example, biological mediators such as retinoid acid, which induces apoptosis of ATL cells in vitro, may reduce drug resistance and stimulates immunity to restore anti-tumour activity against ATL cells. Alternatively, immunotherapy with anti-interleukin-2 receptor monoclonal antibodies or injection of cytotoxic T-cells directed against virus antigens could be interesting approaches which may merit further investigations in the near future. Finally, the recent demonstration that the combination of arsenic trioxide (As) and IFN induces a specific degradation of the viral transactivator Tax followed by cell cycle arrest and apoptosis of HTLV-I positive cells may constitute a valuable addition to ATL treatment. ************************************************** Leuk Lymphoma 2001 Jan;40(3-4):287-94 The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, Herring B, Derby M, Jackson-Booth PG, Marshall M, Lucy D, Jain A, Cranston B, Hanchard B, Lee CC, Top LE, Fleisher TA, Nelson DL, Waldmann TA Metabolism Branch, National Cancer Institute, University of the West Indies, Kingston, Jamaica. [Medline record in process] Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy with a poor survival despite aggressive multiagent chemotherapy. The combination of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has been reported to induce remissions in patients with ATL. The purpose of this study was to evaluate the clinical response and toxicity following administration of a combination of IFNalpha-2b and AZT in patients with human T-cell lymphotropic virus type I (HTLV-I)-associated ATL. Eighteen patients with ATL (chronic. crisis, acute or lymphoma type) were treated with the combination of AZT (50 - 200 mg orally 5 times a day) and IFNalpha-2b (2.5 - 10 million units subcutaneously daily). Three patients had objective responses lasting more than one month. One patient had a clinical complete remission, lasting 21.6 months and two patients had partial remissions lasting 3.7 and 26.5 months. Six patients were not considered evaluable for response due to short and/or interrupted periods of treatment. Seventeen patients have died with a median survival time after initiation of therapy of 6 months. Neutropenia and thrombocytopenia were the dose limiting toxicities. In conclusion, the response rate in this study was lower than noted in the two previous published series. This may be due to the amount and type of prior treatment our patients had received. ************************************************ Br J Haematol 2001 May;113(2):375-82 A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M Department of Laboratory Medicine, Nagasaki University, Nagasaki, Japan. [email protected] This phase II trial was performed to evaluate the efficacy of a new granulocyte colony-stimulating factor (G-CSF)-supported multi-agent chemotherapy protocol, LSG15, for aggressive adult T-cell leukaemia-lymphoma (ATL). Ninety-six previously untreated patients with aggressive ATL were enrolled and grouped as: acute type (58), lymphoma type (28) and unfavourable chronic type (10). Therapy consisted of seven cycles of VCAP (vincristine, cyclophosphamide, doxorubicin and prednisone), AMP (doxorubicin, ranimustine and prednisone) and VECP (vindesine, etoposide, carboplatin and prednisone). G-CSF was administered during the intervals between chemotherapy until neutrophil reconstitution was achieved. Eighty-one per cent of the 93 eligible patients responded [95% confidence interval (CI), 71.1-88.1%], with 33 patients obtaining complete response (35.5%) and 42 obtaining partial response (45.2%). The median survival time (MST) after registration was 13 months and the median follow-up duration of the 20 surviving patients was 4.2 years (range 2.8-5.6). Overall survival at 2 years was estimated to be 31.3% (95% CI, 22.0-40.5%). Grade 4 haematological toxicity of neutropenia and thrombocytopenia were observed in 65.3% and 52.6% of the patients respectively, but grade 4 non-haematological toxicity was observed in only one patient. LSG15 is feasible with mild non-haematological toxicity and improved the clinical outcome of ATL patients. MST and overall survival at 2 years were superior to those obtained by our previous trials.

אסטרלסי שלום דיסטימיה היא שם שניתן מצב של דכאון מתמשך כרוני בעצמה נמוכה ניתן לטפול בפסיכותרפיה בגישות שונות או בתרופות (או שלוב) השתנת יתר כעקרון אינה מסוכנת כפוף לכמויות ולתדירות מדוע את בטוחה שזה מבונסרין אנא פני לרופא המשפחה לברור , אם אכן מבונסרין וזה בעייתי ניתן לשנות את התרופה בהצלחה עמי

וירוס זה אכן קשור וכנראה הוא הגורם לסוג מיוחד של לאוקמיה / לימפומה הנקראת Adult T-cell leukemia / lymphoma נפוצה בעיקר ביפן ובקריביים, אך מתרחשת גם במקומות אחרים בצורה ספורדית. בארץ היו מספר מקרים של חולים ולחלק מהם היה מוצא משותף - מאיזור משהד בפרס. למחלה מספר צורות ביטוי; צורה אקוטית, צורה כרונית, צורה "זוחלת". הפרוגנוזה מתשנה לפי הביטוי, אך אינה טובה בד"כ. בין ביטויי המחלה : הגדלת בלוטות, הגדלת כבד וטחול, נגעים עוריים, נגעים / חורים בעצמות והיפרקלצמיה (=עליה בסידן בדם), ביטויים נוירולוגיים, עליה במספר הלימפוציטים בדם. הטיפול הוא כמו בלימפומות אחרות, כימותרפיה, אבל לא תמיד זה מועיל. יש דיווחים של טיפולים יותר יעילים המשלבים AZT ואינטרפרון, אבל הדבר לא ברור עדיין די הצורך: תקציר The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, Herring B, Derby M, Jackson-Booth PG, Marshall M, Lucy D, Jain A, Cranston B, Hanchard B, Lee CC, Top LE, Fleisher TA, Nelson DL, Waldmann TA Metabolism Branch, National Cancer Institute, University of the West Indies, Kingston, Jamaica. [Medline record in process] Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy with a poor survival despite aggressive multiagent chemotherapy. The combination of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has been reported to induce remissions in patients with ATL. The purpose of this study was to evaluate the clinical response and toxicity following administration of a combination of IFNalpha-2b and AZT in patients with human T-cell lymphotropic virus type I (HTLV-I)-associated ATL. Eighteen patients with ATL (chronic. crisis, acute or lymphoma type) were treated with the combination of AZT (50 - 200 mg orally 5 times a day) and IFNalpha-2b (2.5 - 10 million units subcutaneously daily). Three patients had objective responses lasting more than one month. One patient had a clinical complete remission, lasting 21.6 months and two patients had partial remissions lasting 3.7 and 26.5 months. Six patients were not considered evaluable for response due to short and/or interrupted periods of treatment. Seventeen patients have died with a median survival time after initiation of therapy of 6 months. Neutropenia and thrombocytopenia were the dose limiting toxicities. In conclusion, the response rate in this study was lower than noted in the two previous published series. This may be due to the amount and type of prior treatment our patients had received. עוד תקציר: Adult T-cell lymphoma/leukemia is caused by infection with the retrovirus human T-cell lymphotropic virus type I and is frequently associated with hypercalcemia, circulating leukemic cells, bony and skin involvement, a rapidly progressive course, and poor response to chemotherapy.[58] The combination of zidovudine and interferon alfa has activity against adult T-cell leukemia/lymphoma, even for patients who failed prior cytotoxic therapy. Durable remissions are seen in two-thirds of presenting patients with this combination, but long-term disease-free survival rates are not yet available.[59,60] עוד קישורים: http://cancer.med.upenn.edu/pdq_html/cites/10/10025.html http://cancer.med.upenn.edu/pdq_html/cites/10/10778.html תקציר http://www.john-libbey-eurotext.fr/articles/hma/2/4/312-20/en-resum.htm על הוירוס http://sites.netscape.net/derekwongkk/viruses/HTLV.htm http://www.usc.edu/hsc/info/pr/1vol1/102/hiv.html